Dyne Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
DYN$17.92-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Loss · AccumulatedDeficit · Stockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share data) · Shares · Amount | ||||||
| Balance at January 1, 2022 | 51,569,381 | $6 | $596,934 | $(269) | $(228,474) | $368,197 |
| Issuance of common stock in at-the-market offering, net of issuance costs of $1.2 million | 3,425,085 | — | 36,861 | — | — | 36,861 |
| Exercise of stock options | 314,272 | — | 529 | — | — | 529 |
| Stock-based compensation | — | — | 15,178 | — | — | 15,178 |
| Vesting of restricted shares | 38,141 | — | — | — | — | — |
| Vesting of restricted stock units | 289,626 | — | — | — | — | — |
| Unrealized losses on marketable securities | — | — | — | (302) | — | (302) |
| Net loss | — | — | — | — | (168,099) | (168,099) |
| Balance at December 31, 2022 | 55,636,505 | 6 | 649,502 | (571) | (396,573) | 252,364 |
| Issuance of common stock in at-the-market offering, net of issuance costs of $1.8 million | 4,509,063 | — | 52,369 | — | — | 52,369 |
| Exercise of stock options | 832,906 | — | 1,953 | — | — | 1,953 |
| Stock-based compensation | — | — | 19,972 | — | — | 19,972 |
| Vesting of restricted stock units | 490,269 | — | — | — | — | — |
| Unrealized gains on marketable securities | — | — | — | 571 | — | 571 |
| Net loss | — | — | — | — | (235,937) | (235,937) |
| Balance at December 31, 2023 | 61,468,743 | 6 | 723,796 | — | (632,510) | 91,292 |
| Issuance of common stock in public offering, net of issuance costs of $44.3 million | 31,797,500 | 3 | 675,177 | — | — | 675,180 |
| Issuance of common stock in at-the-market offering, net of issuance costs of $3.3 million | 3,800,465 | 1 | 97,870 | — | — | 97,871 |
| Exercise of stock options | 4,181,133 | — | 37,043 | — | — | 37,043 |
| Stock-based compensation | — | — | 45,864 | — | — | 45,864 |
| Vesting of restricted stock units | 1,070,788 | — | — | — | — | — |
| Unrealized gains on marketable securities | — | — | — | 6 | — | 6 |
| Net loss | — | — | — | — | (317,418) | (317,418) |
| Balance at December 31, 2024 | 102,318,629 | $10 | $1,579,750 | $6 | $(949,928) | $629,838 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.